why does nobody talk about shortage list
Genuine question, and the title is the question: why does nobody talk about shortage list.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
A 503A pharmacy compounds for an identified patient against a prescription. A 503B outsourcing facility registers with the regulator, may produce without patient-specific prescriptions, and is subject to current good manufacturing practice requirements. The two are governed differently and the difference is not cosmetic.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Push back: "compounded is fine because a pharmacy made it" skips every question this board exists to ask.
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
the pharmacy and the prescriber are two separate questions
salt forms are the recurring argument and the answer is boring
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
shortage status changes and the whole arrangement changes with it
the price difference is mostly the intake, not the vial
compounded is not generic, there is no equivalence claim
Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.
ask what the beyond-use date is based on
Who is the prescriber, and are they the same organisation as the pharmacy?
503A is patient-specific, 503B is outsourcing facility, they are not the same thing
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
Asked for potency testing on the finished preparation. They had it. I had assumed they would not.
Was there potency testing on the finished preparation, or only on the starting material?
ask which facility, then ask for their testing
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
a 503B has to register and report, so there is a paper trail to ask for
This. Compounded preparations carry no equivalence claim, and treating them as generics is a category error people make constantly.
- 1Who is the prescriber, and are they the same organisation as the pharmacy?9 comments in this branch · started by u/kavya_kravchenko
- 2Salt form matters for mass: a preparation specified as one salt and dosed as…8 comments in this branch · started by u/sofia_nascimento